



Medical Compression System (D.B.N.) Ltd.

January 31, 2010

Israel Securities Authority
via MAGNA

Tel Aviv Stock Exchange Ltd.
via MAGNA

re: **Company notification of penetration to four additional medical centers in the USA**

To whom it may concern,

Medical Compression System (D.B.N.) Ltd. ("Company") today announced that four additional medical centers in the USA, in Ohio, Virginia and Maryland, had selected the Company's product, ActiveCare + S.F.T.[®], for post surgery DVT prevention treatment. Approximately 6,000 relevant procedures are performed annually at these medical centers. The Company expects that in the coming year of activity, the penetration rate of the product to these centers will be approximately 15% of all procedures performed, equaling about 900 procedures per annum. The Company further believes that the aggregate rate of penetration of the product at the 12 medical centers in the US in which it is active will be approximately 30%, equaling about 4,500 procedures per annum.

The estimates of the Company included in this report, including regarding the scope of the Company's activity constitute forward-looking statements, as defined in the Securities Law, 5728 – 1968, and there is no guarantee that said statements will materialize. The Company's estimates are based on business assumptions, past experience and professional information. These estimates may not materialize, in whole or in part, or materialize materially differently than expected by the Company, and this for various reasons, including a change in market trends, competition, global or local economic situation and regulatory changes.

The Company's press release is hereby attached.

Sincerely,

Medical Compression System (D.B.N.) Ltd.

Medical Compression Systems (D.B.N.) Ltd, 2 Ha'Ilan St, Or Akive, 30600
Tel: +972-4-626-6630, Fax: +972-4-626-6640
www.mcsmed.com



In January 2010, Medical Compression System (MCS) increases its presence in the US by 50% with its product ActiveCare + S.F.T.®

Four new medical centers have begun using the Company's product in addition to the eight centers that currently use it

6,000 relevant procedures are performed at these medical centers annually; the Company expects that in the coming year its penetration rate of these centers will be approximately 15%

Medical Compression System (MCS), today (January 31, 2010) announced that four additional medical centers in the USA, in Ohio, Virginia and Maryland, had selected the Company's product, ActiveCare+ S.F.T.®, for treatment to prevent DVT after surgery.

Approximately 6,000 relevant procedures are performed annually at these medical centers. The Company expects that in the coming year of activity, the penetration rate of the product to these centers will be approximately 15% of all procedures performed, equaling about 900 procedures.

The Company further believes that the aggregate rate of penetration of the product at the 12 medical centers in the US in which it is active will be approximately 30%, equaling about 4,500 procedures.

Adi Dagan – CEO said, "We are delighted to announce that in our first month of activity in 2010, we were able to penetrate four more leading medical centers, and over the past three months have doubled our footprint in the US with SFT. We hope that these successes will lead to marked growth in the number of procedures in which the Company's product is used. The Company's product, ActiveCare + S.F.T.®, is currently used at 12 leading medical centers. We believe that this distribution will enable the continued penetration and marketing of the product to additional medical centers interested in more innovative and safer treatment offered by the Company's product."

-contd-



About the Company

The Company is engaged in the field of non-invasive medical devices and has developed a device to prevent deep vein thrombosis (DVT) as a result of trauma or surgical intervention. The Company has received FDA approval to market and sell its products in the US and CE approval to market and sell its products in Europe.

Forward-looking statements

The Company's estimates included in this publication, including with respect to the volume of its activity, constitute forward-looking information as defined in the Securities Law, 5728 – 1968 and it is not at all certain that said statements will materialize. The Company's estimates are based on business assumptions, past experience and professional information. These estimates may not materialize, in whole or in part, or differ materially from what the Company expects, for various reasons, including a change in market trends, competition, global or local economic situation and regulatory changes.

###